SCHEMBL3582333

SCHEMBL3582333

ClCCCOc1ccc(-c2nc3c(s2)CCNC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 5/20 0.45
CD274 Q9NZQ7 5/20 0.45
TLR9 Q9NR96 2/20 0.41
TLR7 Q9NYK1 2/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
LMNA P02545 1/20 0.35
ATP4A P20648 2/20 0.34
ATP4B P51164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
ADORA2A P29274 1/20 0.33
TLR8 Q9NR97 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579620 0.91 PPARD (0.43) PDCD1CD274PPARDPPARAMAPT
SCHEMBL3584441 0.90 PDCD1 (0.50) PDCD1CD274TLR9TLR7PPARD
SCHEMBL3669195 0.82 PDCD1 (0.52) PDCD1CD274TLR9TLR7RAB9A
SCHEMBL30785589 0.79 PDCD1 (0.52) PDCD1CD274TLR9TLR7TLR8
SCHEMBL3569806 0.79 HRH3 (0.54)
SCHEMBL3582060 0.76 HRH3 (0.49) PPARDPPARAMAPTRAB9ALMNA
SCHEMBL15164318 0.76 PDCD1 (0.52) PDCD1CD274TLR9TLR7TLR8
SCHEMBL1262023 0.76 PDCD1 (0.52) PDCD1CD274TLR9TLR7TLR8
SCHEMBL4050576 0.76 MAOA (0.33) PDCD1CD274PPARDPPARAMAPT
SCHEMBL12491614 0.76 PDCD1 (0.69) PDCD1CD274TLR9TLR7RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
EP-2049548-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB Pharma, S.A. (BE) 2009-04-22 EP disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands HRH3, HRH4, HRH2 PDCD1 1185/4885CD274 487/4885TLR9 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.